Table 3.
Quantification of SP1 in 8 seroconversion panels
| Panel no. | Time from 1st sample (h) | Viral load (copies/ml)a | Total spliced (%)b | SP1 (copies/ml)c | SP1 gel resultd | HBsAg (IU/ml)e |
|---|---|---|---|---|---|---|
| 912 | 0 | 1.54E+02 | 0 | 0 | − | <1 |
| 5 | 2.95E+02 | 0 | 0 | − | <1 | |
| 7 | 3.64E+02 | 0 | 0 | − | <1 | |
| 12 | 4.06E+02 | 0 | 0 | − | <1 | |
| 17 | 1.03E+03 | 0 | 0 | − | <1 | |
| 24 | 2.12E+03 | 0 | 0 | − | <1 | |
| 42 | 7.42E+03 | 0 | 0 | − | 21 | |
| 47 | 1.15E+04 | 0 | 0 | − | 88 | |
| 906 | 0 | 4.20E+01 | 0 | 0 | − | <1 |
| 137 | 1.60E+03 | 0 | 0 | − | 2.4 | |
| 150 | 3.70E+03 | 0 | 0 | − | 9.5 | |
| 154 | 7.95E+03 | 0 | 43 | + | 17 | |
| 157 | 5.95E+03 | 0 | 36 | + | 38 | |
| 927 | 0 | 1.83E+00 | 0 | 0 | − | <1 |
| 4 | 9.54E+02 | 0 | 0 | − | 1.3 | |
| 7 | 2.54E+03 | 0 | 0 | − | 3.1 | |
| 11 | 2.79E+03 | 31 | 0 | − | 11 | |
| 14 | 5.17E+03 | 25 | 0 | − | 25 | |
| 18 | 1.25E+04 | 67 | 0 | + | 78 | |
| 928 | 0 | 2.02E+02 | 0 | 0 | − | − |
| 2 | 3.41E+02 | 0 | 0 | − | − | |
| 7 | 4.82E+02 | 0 | 0 | − | − | |
| 9 | 2.57E+03 | 0 | 0 | − | − | |
| 14 | 3.85E+03 | 0 | 0 | − | + | |
| 16 | 2.00E+04 | 0 | 0 | − | + | |
| 21 | 3.63E+04 | 0 | 26 | + | + | |
| 933 | 2 | 1.00E+01 | 0 | 0 | − | − |
| 7 | 8.30E+02 | 0 | 0 | − | − | |
| 9 | 1.20E+03 | 0 | 0 | − | − | |
| 16 | 6.80E+03 | 0 | 0 | − | − | |
| 144 | 1.30E+07 | 0 | 6.00E+03 | + | + | |
| 921 | 0 | 4.06E+02 | 0 | 0 | − | 3.5 |
| 5 | 4.89E+03 | 0 | 0 | − | 7 | |
| 7 | 5.86E+03 | 0 | 0 | − | 17 | |
| 12 | 1.97E+04 | 70 | 24 | + | 70 | |
| 14 | 2.83E+04 | 83 | 43 | + | 156 | |
| 19 | 3.37E+05 | 84 | 98 | + | >400 | |
| 932 | 0 | 3.31E+00 | 0 | 0 | − | − |
| 25 | 7.00E+00 | 0 | 0 | − | − | |
| 27 | 1.30E+01 | 0 | 0 | − | − | |
| 34 | 3.20E+01 | 0 | 0 | − | − | |
| 41 | 1.56E+02 | 0 | 0 | − | − | |
| 43 | 1.02E+02 | 0 | 0 | − | − | |
| 48 | 2.64E+02 | 0 | 0 | − | − | |
| 50 | 5.10E+02 | 0 | 0 | − | − | |
| 61 | 1.09E+02 | 0 | 0 | − | + | |
| 63 | 9.46E+02 | 0 | 0 | − | + | |
| 69 | 3.66E+03 | 0 | 0 | − | + | |
| 71 | 1.29E+04 | 0 | 0 | − | + | |
| 76 | 1.35E+04 | 0 | 0 | − | + | |
| 83 | 1.60E+04 | 0 | 0 | − | + | |
| 85 | 8.72E+04 | 0 | 0 | − | + | |
| 926 | 0 | 6.00E+01 | 0 | 0 | − | <1 |
| 2 | 3.90E+01 | 0 | 0 | − | <1 | |
| 9 | 2.62E+02 | 0 | 0 | − | <1 | |
| 13 | 4.22E+02 | 0 | 0 | − | 1 | |
| 15 | 8.46E+02 | 0 | 0 | − | 1.9 | |
| 20 | 1.09E+04 | 0 | 0 | − | 3.6 | |
| 23 | 1.17E+04 | 0 | 0 | − | 5 | |
| 27 | 3.89E+04 | 0 | 0 | − | 14 |
HBV DNA viral load was obtained with qPCR as previously described (18).
Total spliced DNA is calculated by subtracting viral load by qPCR with primers from the X region from values obtained with the primers from the spliced S region.
SP1 quantification was obtained with primers outside the core/pol spliced region and a specific probe. In both systems, the standard is a calibrated plasmid containing the full HBV genome.
The gel method consists of amplification of the full HBV genome as described previously (19). Amplicons of different lengths are separated in a polyacrylamide gel, and individual bands are confirmed by sequencing to identify the HBV genome.
HBsAg levels were quantified by microparticle enzyme immunoassay with the Architect instrument (Abbott). A − or + is given where no exact value is available.